Navigation Links
Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
Date:12/20/2007

SOUTH SAN FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire- FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology, commonly referred to as lentiviral vectors. Pursuant to the agreement, Cell Genesys has received a payment of $12 million from GBP IP, LLC in exchange for all intellectual property and previously established licensing agreements relating to its lentiviral gene delivery technology. Cell Genesys will retain rights to use the technology for research and development purposes, including potential future use with cancer immunotherapy products.

"We are pleased to have entered into this agreement with GBP IP, LLC and Lentigen, a leader in the field of lentiviral gene delivery technology, and wish them every success in the further development of this important technology," stated Robert Tidwell, senior vice president of corporate development at Cell Genesys. "This agreement reflects Cell Genesys' ongoing commitment and ability to leverage its non-core business assets and in so doing build shareholder value."

Over the years, Cell Genesys has successfully leveraged its non-core business assets through strategic spin outs and outlicensing agreements. In 1996, Cell Genesys spun out its antibody technology creating Abgenix, a company that was acquired in 2005 by Amgen for approximately $2.6 billion. In 2001, Cell Genesys launched Ceregene, a privately held company that is focused on developing gene therapies for neurodegenerative disorders. Cell Genesys currently holds a
'/>"/>

SOURCE Cell Genesys, Inc.; GBP IP, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... September 30, 2014 Shimadzu Scientific ... an easy-to-use and highly precise tool for measuring ... considerable elongation. With 1000-mm maximum movement distance, the ... for a gauge length of 10 mm. In ... accuracy above 50-mm stroke and within +/- 100 ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... ... as the sample collection kit for MyCeliacID™ a saliva-based genetic test dedicated to celiac ... sample collection challenges inherent with traditional collection methods which are often too costly and ... Ottawa, ...
... , CANTON, Mass., Aug. 18 ... than 500 pieces of state-of-the-art R&D equipment that is no ... EquipNet as the exclusive seller and listed the premium lab ... online venue for pre-owned equipment. , , ...
... , , , , ... Inc., (NYSE: CRY ) an implantable biological medical device ... of the CryoPatch((R)) SG pulmonary human cardiac patch since FDA clearance. ... of Michigan C.S. Mott Children,s Hospital in Ann Arbor, MI by ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Massive Inventory of Premium Lab & Analytical Equipment Now Available 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 4
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... FL. If you think you eat healthier at the Sunburst ... be wrong. You could be a victim of the "Health ... Consumer Research conference in Jacksonville, FL, showed that people eating ... 56% as many calories as they actually did. The ...
... direct evidence that taking up smoking results in epigenetic changes ... reported at the 35th Congress of the European Society for ... smoking and cancer has been established for decades, explained Dr ... Cancer Studies, Birmingham, who presented the results. Smoking is the ...
... lung cancer patients seem to live longer and experience delays ... cancer-associated molecule called MET is added to treatment with erlotinib, ... Dr David Spigel, Director of lung cancer research for the ... findings at the 35th Congress of the European Society for ...
Cached Biology News:Study reveals cancer-linked epigenetic effects of smoking 2New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2
Component of HyperMu™ Insertion Kit...
Request Info...
... , Maintenance 112 days/each ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ... 100 ml blood (~50 ml serum) x1 each , ...
... g protein in 200 l SDS-PAGE Western blotting ... Abelson transformed macrophage cells, whole ... should be stored at -20C ... sample vial should be boiled ...
Biology Products: